Miscellaneous (e.g., Hydrocarbons, Etc.) Patents (Class 514/789)
-
Publication number: 20090060842Abstract: In a method for diagnosis and treatment of a patient with regard to prostatitis, a differential diagnosis of prostatitis versus prostate cancer and/or BPH is conducted on a patient using a cost-effective diagnosis method. Given diagnosed prostatitis, a cost-effective decision test is implemented on the patient to determine whether the patient exhibits complaints locally in the region of the prostate or in the rest of the body. A molecular inflammation marker is administered to the patient, wherein a cost-effective imaging method is implemented in the region of the prostate of the patient given local complaints or a cost-intensive imaging method is implemented on the entire patient given complaints in the rest of the body. An inflammation-inhibiting treatment is implemented in the body region of the patient that is detected as inflamed via the respective imaging method.Type: ApplicationFiled: September 3, 2008Publication date: March 5, 2009Inventors: Jens Fehre, Ralf Nanke, Martin Stetter
-
Publication number: 20090057337Abstract: In the production of diluted solutions in different concentrations, in each case an amount of a concentrate and an amount of a diluent are mixed. The ratio of the two amounts is never changed. The different concentrations of the diluted solutions result from concentrates of different concentrations that are used.Type: ApplicationFiled: November 7, 2008Publication date: March 5, 2009Inventor: Hans Georg Hagleitner
-
Publication number: 20090060983Abstract: The present invention relates to a process for making orally disintegrating dosage forms and means for packaging such dosage forms.Type: ApplicationFiled: August 30, 2007Publication date: March 5, 2009Inventors: Frank J. Bunick, Joe Luber
-
Publication number: 20090048659Abstract: According to one aspect of the present invention, implantable or insertable medical devices are provided, which contain sol-gel derived ceramic regions which have molded submicron surface features.Type: ApplicationFiled: August 17, 2007Publication date: February 19, 2009Applicant: Boston Scientific Scimed, Inc.Inventors: Jan Weber, Liliana Atanasoska, Michele Zoromski, Robert W. Warner
-
Publication number: 20090047366Abstract: The present invention is a method to accelerate the coagulation of blood through the application of inorganic materials to the wound of a patient on anticoagulant or platelet blocker therapy. The method comprises contacting such wounds with a substance selected from the group consisting of zeolitic molecular sieves and non-zeolitic molecular sieves, diatomaceous earth, glass powder or fibers, precipitated or fumed silica, kaolin and montmorillonite clays and Ca exchanged permutites.Type: ApplicationFiled: August 15, 2007Publication date: February 19, 2009Inventors: Robert L. Bedard, Carl N. Zenz
-
Publication number: 20090041821Abstract: Cleaning of a medical probe is provided by a gel layer deposited on a carrier to form a cleaning element. The gel has a tacky surface and is impregnated with a disinfecting agent. After contacting the patient's body surface, the medical probe surface is cleaned by pressing it against the gel surface. The soiling particles that were carried by the probe will be adhered to a gooey layer. The used cleaning element is discarded after cleaning.Type: ApplicationFiled: August 9, 2007Publication date: February 12, 2009Inventor: Jacob Fraden
-
Publication number: 20090043346Abstract: Cells that are in the process division are vulnerable to damage by AC electric fields that have specific frequency and field strength characteristics. The selective disruption of rapidly dividing cells can therefore be accomplished by imposing an AC electric field in a target region for extended periods of time. Some of the cells that divide while the field is applied will be damaged, but the cells that do not divide will not be harmed. This selectively damages or disrupts rapidly dividing cells like parasites, but does not harm normal cells that are not dividing.Type: ApplicationFiled: August 13, 2008Publication date: February 12, 2009Inventors: Yoram Palti, Moshe Giladi
-
Patent number: 7479384Abstract: Disclosed are two nucleic acid molecules from M. incognita encoding malate dehydrogenase-like (MDH-like) polypeptides. The MDH-like polypeptide sequences are also provided, as are vectors, host cells, and recombinant methods for production of MDH-like nucleotides and polypeptides. The invention further relates to screening methods for identifying inhibitors and/or activators, as well as methods for antibody production.Type: GrantFiled: April 6, 2004Date of Patent: January 20, 2009Assignee: Divergence, Inc.Inventors: Andrew P. Kloek, Brandy Salmon, Deryck Jeremy Williams
-
Publication number: 20090018218Abstract: Disclosed are methods of inhibiting, regulating, and/or modulating the formation of soluble, globular, non-fibrillar, neurotoxic amyloid ?1-42 oligomers from amyloid ?1-42 monomers. Also disclosed are methods of treating a patient suffering from diseases associated with the formation of soluble, globular, non-fibrillar, neurotoxic amyloid ?1-42 oligomers.Type: ApplicationFiled: July 12, 2007Publication date: January 15, 2009Inventors: Grant A. Krafft, Todd Pray, William F. Goure
-
Publication number: 20090017090Abstract: Described here are devices, methods, and kits for treating sinusitis and related respiratory conditions by locally delivering active agents to the osteomeatal complex over a sustained period of time. The devices may be passively fixed within the osteomeatal complex and/or include one or more features that actively fix it within the osteomeatal complex. The devices may optionally include a portion that extends into a sinus ostium, sinus cavity, and/or the nasal passage to deliver an active agent.Type: ApplicationFiled: July 9, 2007Publication date: January 15, 2009Inventors: Patrick A. ARENSDORF, Danielle L. Biggs, Rodney Brenneman, David B. Downie, Donald J. Eaton, Thomas R. Tice
-
Publication number: 20090012186Abstract: The present invention relates to a novel mite composition comprising a population of the phytoseiid predatory mite species Amblyseius swirskii. and a factitious host population, which may be employed for rearing said phytoseiid predatory mite species or for releasing the phytoseiid predatory mite species in a crop. According to further aspects the invention relates to a method for rearing the phytoseiid predatory mite species Amblyseius swirskii, to the use of the mite composition and to a method for biological pest control in a crop, which employ the mite composition.Type: ApplicationFiled: December 31, 2004Publication date: January 8, 2009Inventors: Karel Jozef Florent Bolckmans, Yvonne Maria Van Houten
-
Publication number: 20090004285Abstract: The present invention is a stable, non-disintegrable dosage form which combines the benefits of a microencapsulated substrate with the convenience of direct compression. The present invention is also directed to methods for producing directly compressed microencapsulated dosage forms to provide modified release and dosage form stability. The dosage unit can have a high active load.Type: ApplicationFiled: June 29, 2007Publication date: January 1, 2009Inventors: Liangping Yu, Paul H. Richardson
-
Publication number: 20080317673Abstract: A method for diagnosing and treating a bronchial asthma by classifying a patient's asthma as Type I, Type II or Type III based on the patient's symptoms is disclosed. The symptoms for the three types of asthma are disclosed together with recommended treatment guidelines for each type to optimize treatment regiments based on symptoms.Type: ApplicationFiled: June 20, 2007Publication date: December 25, 2008Inventor: Fatema Salem Al-Thallab
-
Publication number: 20080317867Abstract: The present invention provides a cosmetic system for disguising dermatological blemishes. The cosmetic system includes a viscous silicone material and a catalyst. The silicone material is pigmented with a cosmetic pigment according to a selected skin tone. In one aspect, the cosmetic system also includes a flocking agent. The flocking agent is mixed within the silicone material or the catalyst to provide texture. The cosmetic system also includes at least two cartridges. The cartridges hold the viscous silicone material and the catalyst, separately. Optionally, the cosmetic system includes a dispensing gun. The dispensing gun has a tip through which the silicone material and the catalyst may be dispensed, whereupon the silicone material and the catalyst are mixed and applied to a user's skin for curing. A method for disguising dermatological blemishes is also provided herein.Type: ApplicationFiled: June 20, 2007Publication date: December 25, 2008Inventor: Matthew A. Singer
-
Publication number: 20080317835Abstract: Assays are preformed to determine nutrient deficiency levels in an individual to address the deficiencies and improve health and longevity. Nutraceutical and cosmeceutical products containing nanoencapsulated active ingredients are provided, in addition to dietary, exercise, sleep, and other lifestyle recommendations.Type: ApplicationFiled: June 20, 2007Publication date: December 25, 2008Inventors: Nazli Azimi, Mohammad Saeed Kharazmi
-
Publication number: 20080311090Abstract: The present invention is related to a method for modulating expression of protein kinase C-alpha associated with proliferative diseases. The invention further relates to a screening method utilizing the association between transcription factors (MZF-1 and Elk-1) and their DNA binding element (PKC-.alpha. promoter) to identify novel anticancer agents.Type: ApplicationFiled: June 15, 2007Publication date: December 18, 2008Applicant: CHUNG SHAN MEDICAL UNIVERSITYInventors: Jer-Yuh Liu, Yi-Hsien Hsieh
-
Publication number: 20080305096Abstract: A method of providing controlled release of a biologically active substance within a subject's digestive system. The biologically active substance is administered concurrently with one or more soluble fibers in an oral dosage unit. The soluble fibers interact with the biologically active substance within the subject's digestive system to moderate and control the release of the biologically active substances in the subject's bloodstream. This provides more constant blood concentrations of the biologically active substances. The amount of soluble fibers in the oral dosage unit is greater than 40% by weight, and in some cases greater than 50% by weight of the oral dosage unit. The oral dosage unit typically contains from about 1 to 15g of soluble fiber, and in some cases from about 3 to 5g of soluble fiber. The biologically active substance may contain phytonutrients that promote the subject's cardiovascular system, immune system, or weight management.Type: ApplicationFiled: June 7, 2007Publication date: December 11, 2008Applicant: UNICITY INTERNATIONAL, INC.Inventors: Peter J. E. Verdegem, Stewart F. Hughes, Curtis A. Hedges, G. Paulo Bangerter
-
Publication number: 20080299110Abstract: The present invention provides methods, reagents and kits for diagnosing and/or for the prognosis of non-autoimmune acute joint inflammation by detecting cytokine biomarkers in a sample obtained from an individual thought to be suffering from joint injury. The cytokine biomarkers used with the methods and kits of the present invention are IL-6, MIP-1?, MCP1 and IFN?.Type: ApplicationFiled: June 1, 2007Publication date: December 4, 2008Inventor: Gaetano J. Scuderi
-
Publication number: 20080293830Abstract: A method for activating an efferent sympathetic nerve innervating an adipose tissue and improving obesity-associated symptoms is provided, comprising stimulating an afferent vagal nerve from the liver without directly enhancing peroxisome proliferator-activated receptor (PPAR)-?2 function in the liver.Type: ApplicationFiled: May 21, 2007Publication date: November 27, 2008Applicant: TOHOKU UNIVERSITYInventors: Hideki KATAGIRI, Yoshitomo OKA, Tetsuya YAMADA, Kenji UNO
-
Publication number: 20080292682Abstract: A method for treating oleoresin induced allergic dermatitis by topically contacting an affected area with a therapeutically effective amount of one or more biopolymers for a sufficient amount of time to enable the one or more biopolymers to have an effect and removing the one or more biopolymers from the affected area. The oleoresin can be urushiol, isosolenopsin A, or a combination thereof. The one or more biopolymer can be albumin. The one or more biopolymers can provide a localized anti-inflammatory effect.Type: ApplicationFiled: May 25, 2007Publication date: November 27, 2008Applicant: BOVAL COMPANY, L.P.Inventor: Cody L. Yarborough
-
Publication number: 20080292683Abstract: Compositions are provided that include water soluble or water dispersible film shreds, a carrier and an active, such as, but not limited to a drug, flavoring agent or coloring agent. Also provided are methods of use of the film shreds, such as in improving the dissolution, stability, aesthetics, or taste of a composition or its components, and in reducing a disease risk associated with an active.Type: ApplicationFiled: May 24, 2007Publication date: November 27, 2008Inventors: Pradeep Sanghvi, Richard C. Fuisz
-
Publication number: 20080286372Abstract: Methods for treating a vascular disease by delivering therapeutic compositions with enhanced endothelium targeting are disclosed.Type: ApplicationFiled: May 16, 2007Publication date: November 20, 2008Applicant: Abbott Cardiovascular Systems Inc.Inventors: Stephen Pacetti, Syed Faiyaz Ahmed Hossainy, Florian Niklas Ludwig
-
Publication number: 20080279921Abstract: The present invention relates to improved methods of formulations of hydrophobic photosensitizers, and their precursors, for mucosal administration. The formulation of the invention comprises of hydrophobic photosensitizers which have been incorporated into suitably sized liposomes. Additionally, these formulations include the incorporation of PS-loaded liposomes into a copolymer matrix. The liposome of the present invention allows the hydrophobic photosensitizers to be incorporated into the thermogel matrix and thus promoting intimate contact between the formulation and the mucosal layer for enhanced drug absorption.Type: ApplicationFiled: May 7, 2007Publication date: November 13, 2008Inventors: Volker Albrecht, Dietrich Scheglmann
-
Publication number: 20080274163Abstract: A nose and throat anti-influenza solution is described that decreases the likelihood influenza infection and its spread. The solution's components are readily available and have been used to treat humans for other ailments previously, leading to an easily implemented, scalable, safe, and cost-effective solution. The core components of the solution include: specially denatured alcohol (SDA); Triton x-100; sodium saccharin; 1,8 cineole (eucalyptol); thymol; methyl salicylate; menthol; sorbitol and/or glycerin; sodium benzoate; poloxamer 407; polysorbate 80; and distilled water. Optionally, the solution also includes one or more of the following: citric acid; sambucus nigra agglutinin; a lectin that binds 2,3 sialic acid; nonoxynol-9; sialyllactose; a protease; a protease inhibitor; and/or chloroquine. The solution is applied to the nasal cavity via a pre-moistened cotton swab or a pre-moistened facial tissue and the solution is applied to the back of the throat via a spray, gum, or gargle solution.Type: ApplicationFiled: May 2, 2007Publication date: November 6, 2008Inventors: Steve W. Schwartz, Greg Poole
-
Publication number: 20080260768Abstract: Protein antigens from Streptococcus pneumoniae are disclosed, together with nucleic acid sequences encoding them. Their use in vaccines and in screening methods is also described.Type: ApplicationFiled: April 18, 2007Publication date: October 23, 2008Applicant: Sanofi Pasteur LimitedInventors: Christophe Francois Guy Gilbert, Philip Michael Hansbro
-
Publication number: 20080262108Abstract: The invention provides methods of screening test compounds for their ability to reduce retention of atherogenic lipoproteins in atherogenesis by measuring their activity as a modulator of the binding affinity of CEL (Carboxyl Ester Lipase) to various receptors. The invention further provides methods for the use of active modulators of the binding affinity of CEL to receptors for the prevention and treatment of atherosclerosis.Type: ApplicationFiled: April 1, 2005Publication date: October 23, 2008Inventors: Karl Gunnar Bjursell, Jeanette Annika Nilsson, Sara Ellmark
-
Publication number: 20080262109Abstract: A method for producing a liquid preparation having a solid body content and the resulting liquid preparation. According to the method, the addition of at least a portion of the solid bodies takes place only (a) in the last stage of the method preceding the pouring of the liquid preparation into a packing unit or (b) during the pouring into a packing unit.Type: ApplicationFiled: October 17, 2007Publication date: October 23, 2008Inventors: Bernhard ORLICH, Bernd RICHTER, Alexander LAMBOTTE
-
Publication number: 20080255253Abstract: The present invention provides an animal model for prostatic stromal hyperplasia, and a method for screening for a substance effective for preventing/treating human benign prostatic hyperplasia using the animal model. The animal model for prostatic stromal hyperplasia is produced by implanting the fetal urogenital sinus of a non-human animal under the skin or beneath the prostatic capsule of a non-human animal belonging to the species of the same as or different from the said animal. A substance effective for preventing/treating human benign prostatic hyperplasia can be screened by administering a test substance to the animal model and measuring the preventive or therapeutic effect of the test substance upon the implanted tissue (fetal urogenital sinus or tissue derived therefrom).Type: ApplicationFiled: June 12, 2008Publication date: October 16, 2008Applicant: TAIHO PHARMACEUTICALS CO., LTD.Inventors: Nobuyuki Oda, Kazuhisa Miyoshi, Akihiro Haruno, Hidekazu Miyake
-
Publication number: 20080254074Abstract: A skin care composition for regulating sebum flow from sebocytes is described. The composition comprises spheroids, and optionally, thickening agents and when a spheroid and sebum mixture is made upon application, the resulting mixture leaves a pleasant, silky and powdery sensation.Type: ApplicationFiled: April 11, 2007Publication date: October 16, 2008Applicant: CONOPCO, INC., D/B/A UNILEVERInventors: Anne Dussaud, Pradeep Yadav
-
Publication number: 20080255252Abstract: The present invention relates to a method of diagnosing, or predicting risk of, prostate disease in a subject. More particularly, the invention relates to a method of diagnosing the presence of, or the predisposition to develop, prostate disease in a subject, the method comprising analysing a test sample from the subject for the presence of P. acnes infection of the prostate gland. The present invention further relates to reagents for use in this method and to methods of prevention or treatment of prostate disease.Type: ApplicationFiled: March 15, 2005Publication date: October 16, 2008Applicant: Tissugen Pty. Ltd.Inventors: Ronald Joseph Cohen, Kerryn Lee Garrett, Beverly Anne Shannon
-
Publication number: 20080248997Abstract: The present invention relates to the discovery that the T1R receptors assemble to form functional taste receptors. Particularly, it has been discovered that co-expression of T1R1 and T1R3 results in a taste receptor that responds to umami taste stimuli, including monosodium glutamate. Also, it has been discovered that co-expression of the T1R2 and T1R3 receptors results in a taste receptor that responds to sweet taste stimuli including naturally occurring and artificial sweeteners. Also the present invention relates to the use of hetero-oligomeric taste receptors comprising T1R1/T1R3 and T1R2/T1R3 in assays to identify compounds that respectively respond to umami taste stimuli and sweet taste stimuli. Further, the invention relates to the constitutive of cell lines that stably or transiently co-express a combination of T1R1 and T1R3; or T1R2 and T1R3; under constitutive or inducible conditions.Type: ApplicationFiled: November 13, 2007Publication date: October 9, 2008Applicant: Senomyx, Inc.Inventors: Mark ZOLLER, Xiaodong Li, Lena Staszewski, Shawn O'Connell, Sergey Zozulya, Jon Elliot Adler, Hong Xu, Femando Echeverri
-
Publication number: 20080248996Abstract: The present invention relates to the discovery that the T1R receptors assemble to form functional taste receptors. Particularly, it has been discovered that co-expression of T1R1 and T1R3 results in a taste receptor that responds to umami taste stimuli, including monosodium glutamate. Also, it has been discovered that co-expression of the T1R2 and T1R3 receptors results in a taste receptor that responds to sweet taste stimuli including naturally occurring and artificial sweeteners. Also the present invention relates to the use of hetero-oligomeric taste receptors comprising T1R1/T1R3 and T1R2/T1R3 in assays to identify compounds that respectively respond to umami taste stimuli and sweet taste stimuli. Further, the invention relates to the constitutive of cell lines that stably or transiently co-express a combination of T1R1 and T1R3; or T1R2 and T1R3; under constitutive or inducible conditions.Type: ApplicationFiled: October 31, 2007Publication date: October 9, 2008Applicant: Senomyx, Inc.Inventors: Mark ZOLLER, Xiaodong Li, Lena Staszewski, Shawn O'Connell, Sergey Zozulya, Jon Elliot Adler, Hong Xu, Fernando Echeverri
-
Publication number: 20080242742Abstract: The present invention is based, at least in part, on the generation of an animal model of pancreatic adenocarcinoma which recapitulates the genetic and histological features of human pancreatic adenocarcinoma, including the initiation, maintenance, and progression of the disease. Accordingly, the present invention provides animal models of cancer, e.g., pancreatic adenocarcinoma, wherein an activating mutation of Kras has been introduced, and any one or more known or unknown tumor suppressor genes or loci, e.g., Ink4a/Arf, Ink4a, Arf, p53, Smad4/Dpc, Lkb1, Brca2, or Mlh1, have been misexpressed, e.g., have been misexpressed leading to decreased expression or non-expression. The animal models of the invention may be used, for example, to identify biomarkers of pancreatic cancer, to identify agents for the treatment or prevention of pancreatic cancer, and to evaluate the effectiveness of potential therapeutic agents.Type: ApplicationFiled: August 11, 2006Publication date: October 2, 2008Applicants: Dana-Farber Cancer Institute, Inc., The Trustees of the University of PennsylvaniaInventors: Ronald A. Depinho, Nabeel El-Bardeesy, Andrew J. Aguirre, David A. Tuveson
-
Publication number: 20080242736Abstract: The present invention relates to packaged orally consumable film dosage units for delivery of actives into the oral cavity. In particular, the packaged pharmaceutical product contains a complexate including a complexing agent and an active, an orally consumable film for delivery of the complexate and a package for containing the orally consumable film. The package includes indicia associated therewith. The indicia identifies the complexate as the active ingredient contained in the film, which is as a regulatory approvable chemical entity. The present invention also relates to methods of labeling, pricing, marketing and satisfying governmental regulations for such packaged pharmaceutical products.Type: ApplicationFiled: March 30, 2007Publication date: October 2, 2008Inventor: Richard C. Fuisz
-
Publication number: 20080242737Abstract: The present invention relates to packaged oral delivery systems for delivery of actives into the oral cavity. In particular, the packaged pharmaceutical product contains a complexate including a complexing agent and an active, an oral delivery system for delivery of the complexate and a package for containing the oral delivery system. The package includes indicia associated therewith. The indicia identifies the complexate as the active ingredient contained in the oral delivery system, which is as a regulatory approvable chemical entity. The present invention also relates to methods of labeling, pricing, marketing and satisfying governmental regulations for such packaged pharmaceutical products.Type: ApplicationFiled: March 30, 2007Publication date: October 2, 2008Inventor: Richard Fuisz
-
Publication number: 20080234393Abstract: The present invention relates to compounds and methods for detection and treatment of carcinomas and their precursor lesions. The invention provides DNase nucleic acids and polypeptides useful for the detection and treatment of carcinomas and their precursor lesions. The invention is more specifically related to a method for detection of carcinomas and their precursor lesions comprising the detection of the level and/or the subcellular localization of one or more DNase molecules in biological samples. Furthermore the present invention provides methods for early diagnosis, prognosis and monitoring of the disease course of carcinomas and their precursor lesions as well as for the treatment of said lesions.Type: ApplicationFiled: October 29, 2007Publication date: September 25, 2008Applicant: MTM LABORATORIES AGInventor: Johannes COY
-
Publication number: 20080226759Abstract: A system for treating addictions includes genetic testing to determine the presence of allelic variants of genes shown to be associated with impulsive/addictive behaviors and a tailored rehabilitation regimen of specific physical exercise, special diet and particular dietary supplements to optimize the way mood elevation is achieved in the patient. The system further includes individual and group counseling and initial oxygen therapy. The genetic testing assesses the presence of gene polymorphism in at least one of D2 dopamine receptor gene (DRD2), dopamine transporter gene (DAT1), dopamine beta-hydroxylase gene (DBH) and serotonin transporter (SERT) gene. The dietary supplements are tailored to stimulate production of neuromediators or neurotransmitters, depending upon the polymorphism determined. The exercises include static and dynamic routines also tailored to the results of the genetic testing.Type: ApplicationFiled: March 15, 2007Publication date: September 18, 2008Inventor: Yakov Marshak
-
Publication number: 20080221224Abstract: Macromolecules may be specially designed so that upon adsorption at a substrate, the macromolecules experience intramolecular tension at their covalent bonds due to the physical interaction of the molecular segments of the macromolecules with the substrate. As a result of the induced tension, the macromolecules may be used in a number of applications including, but not limited to, environmental and surface sensors, chemical activators and catalysts, and molecular probes.Type: ApplicationFiled: March 6, 2007Publication date: September 11, 2008Inventor: Sergei S. Sheiko
-
Publication number: 20080221225Abstract: The present invention identifies genes whose gene products are differentially expressed during restenosis, including de novo restenosis and in stent restenosis (ISR). Also provided are therapeutic methods for treating a patient or methods for prophylactically treating an individual susceptible to restenosis. Additionally, the invention describes screening methods for identifying agents that can be administered to treat individuals that have or at risk of developing restenosis.Type: ApplicationFiled: March 7, 2008Publication date: September 11, 2008Inventors: Euan A. Ashley, Thomas Quertermous, Eberhard Grube
-
Publication number: 20080214681Abstract: A method includes contacting a surface in an oral cavity with a first composition capable of reducing a taste of a selected material, and orally administering a second composition separate from the first composition, the second composition including the selected material. The selected material can include a drug, and/or the second composition can further include a drug. In some embodiments, the first and second compositions are included in a kit.Type: ApplicationFiled: August 20, 2007Publication date: September 4, 2008Inventors: Kenan Sahin, Laura Nattress, David Tisi
-
Publication number: 20080214682Abstract: The present invention relates to methods of treating pneumonic plague. More specifically, the present invention relates to methods of using plasmin or Pla inhibitors to treat pneumonic plague.Type: ApplicationFiled: December 21, 2007Publication date: September 4, 2008Applicant: WASHINGTON UNIVERSITY IN ST. LOUISInventors: Wyndham W. Lathem, Virginia Miller, William E. Goldman
-
Patent number: 7419814Abstract: Methods for detecting agents or drugs which inhibit or promote an activity of sphingosine kinase type 2 isoform involving providing a recombinant DNA construct into a cell such that sphingosine kinase type 2 isoform is produced in the cell, adding at least one drug or agent to the cell, and detecting whether or not the drug or agent inhibits or promotes an activity of sphingosine kinase type 2 isoform by measuring sphingosine kinase-depedendent phosphorylation of lipids in the cell and comparing the resultant measurement to a control which did not receive the drug or agent, wherein a decrease in the amount of sphingosine kinase-dependent phosphorylation of the lipids as compared to the control indicates an inhibitory drug or agent, or an increase in the amount of sphingosine kinase-dependent phosphorylation of the lipids in the cell as compared to the control indicates a stimulatory drug or agent.Type: GrantFiled: April 22, 2004Date of Patent: September 2, 2008Assignees: Sankyo Company, Limited, Georgetown UniversityInventors: Sarah Spiegel, Takafumi Kohama
-
Publication number: 20080200566Abstract: The present invention relates to screening methods that make use of a histone deacetylase interacting with a myosin phosphatase for the identification of novel therapeutics useful for inhibiting or inducing apoptosis and for the treatment of pathological conditions, such as smooth muscle cell disorder, cardiac hypertrophy or asthma. Also disclosed are methods for inhibiting or inducing apoptosis and for treatment of a pathological condition by administering to a mammal a therapeutically effective amount of a compound that inhibits or increases the dephosphorylation of a histone deacetylase by a myosin phosphatase or inhibits or increases the binding of a histone deacetylase to a myosin phosphatase.Type: ApplicationFiled: April 27, 2007Publication date: August 21, 2008Applicant: The J. David Gladstone InstitutesInventors: Eric Verdin, Maribel Parra
-
Publication number: 20080200567Abstract: A transgenic non-human animal, in particular a transgenic mouse, encoding Qpct proteins which have been implicated in Qpct-related diseases. Also disclosed are cells and cell lines comprising transgenes encoding for Qpct. Further disclosed are methods and compositions for evaluating agents that affect Qpct, for use in compositions for the treatment of Qpct-related diseases.Type: ApplicationFiled: January 18, 2008Publication date: August 21, 2008Applicant: PROBIODRUG AGInventors: Stephan Schilling, Holger Cynis, Torsten Hoffmann, Hans-Ulrich Demuth, Michael Wermann, Katrin Schulz
-
Publication number: 20080200568Abstract: Genes associated with Type II Diabetes Mellitus (T2DM) are identified and screening methods to identify chemical compounds that act on those targets for the treatment of T2DM or its associated pathologies are discussed. The use of EP3 antagonist was found to affect blood glucose levels in mice fed a high-fat diet and made insulin deficient by streptozocin injection.Type: ApplicationFiled: August 30, 2006Publication date: August 21, 2008Inventor: Stephanie Chissoe
-
Publication number: 20080194710Abstract: Prostatic stem cells have been isolated. Benign prostatic hyperplasia and other proliferative diseases of the prostate may arise in prostatic stem cells. The prostatic stem cells are used as a research tool for studying cancer and other proliferative diseases of the prostate, and for developing diagnostics and therapeutics for proliferative diseases of the prostate. Antibodies to the antigens expressed by prostatic stem cells can be used as therapeutics or diagnostics or can be used to deliver therapeutic or diagnostic agents directly to the prostatic stem cells.Type: ApplicationFiled: May 10, 2005Publication date: August 14, 2008Applicant: NEW YORK UNIVERSITYInventors: Elaine Lynette Wilson, Patricia Burger
-
Publication number: 20080194711Abstract: Multiple sclerosis (MS) is an autoimmune disease of the central nervous system (CNS) characterized by an enormous variability in its clinical presentation and course, in which clear diagnostic parameters are lacking. Here, the inventors performed an RNA screen, which indicated a role for the chemokine receptor CX3CR1 as diagnostic marker Gene expression and flow cytometric analyses demonstrated a significantly lower expression of CX3CR1 in MS patients compared to healthy individuals. Importantly, the inventors also found a correlation between disease activity and frequency of CX3CR1+ NK cells. These findings emphasise the involvement of NK cells in the development and course of MS and provide evidence for CX3CR1 expression to be a marker for MS patients and disease activity.Type: ApplicationFiled: January 19, 2006Publication date: August 14, 2008Inventors: Frauke Zipp-Nitsch, Carmen Infante-Duarte, Claus-Stefen Stuerzebecher
-
Publication number: 20080187928Abstract: Disclosed herein are methods for enhancing one or more effects of exercise in a subject by administering a PPAR? agonist (e.g., GW1516) to the subject in combination with an exercise program. Also disclosed are gene expression profiles unique to the combination of agonist-induced PPAR? activation and exercise. Such profiles are useful, at least, in methods for identifying the use of performance-enhancing drugs in exercised subjects (such as, professional or athletes). Direct interactions between PPAR? and exercised-induced kinases (e.g., AMPK or its subunits, AMPK ?1 and/or AMPK ?2) also are disclosed. Such protein-protein interactions provide new targets for identification of useful compounds.Type: ApplicationFiled: December 28, 2007Publication date: August 7, 2008Inventors: Ronald M. Evans, Vihang A. Narkar, Yong-Xu Wang, Michael Downes, Ruth T. Yu
-
Publication number: 20080188573Abstract: The present invention relates to the use of thy1-FP (fluorescent protein) non-human transgenic animals such as mice to screen for ophthalmic agents that can be used to treat corneal dry eye syndrome and/or retinal neuropathies associated with glaucoma and/or age-related macular degeneration. Such ophthalmic agents may be selected by assessing their ability to provide protection in ocular tissue.Type: ApplicationFiled: February 4, 2008Publication date: August 7, 2008Applicant: ALCON RESEARCH, LTD.Inventors: Ji-Ye WEI, Richard L. ORNBERG, Gustav GRAFF
-
Publication number: 20080176962Abstract: Methods and compositions for rapidly identifying CGEPs required for viral infection of mammalian cells are provided. Also provided are methods of inhibiting viral infection of mammalian cells by inhibiting the activity of one or more CGEPs (e.g., as identified in accordance with methods of the invention) in the cells. Aspects of the invention further include specifically identified CGEPs implicated in mammalian cell infection of specific viruses, e.g., African Swine Fever Virus and Foot and Mouth Virus, and methods of modulating their activity to achieve viral resistance.Type: ApplicationFiled: August 2, 2007Publication date: July 24, 2008Inventors: Stanley N. Cohen, Daniel Rock, Annie Chang, Yanan Feng, Laszlo Zsak, Maria Elisa Piccone